IMC Chicago
ABCL icon

IMC Chicago’s AbCellera Biologics ABCL Stock Holding History

IMC Chicago’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
313,000
+205,000
+190% +$738K ﹤0.01% 3188
2025
Q4 		$369K Buy
108,000
+63,800
+144% +$285K ﹤0.01% 3677
2025
Q3 		$222K Buy
+44,200
New +$195K ﹤0.01% 3521

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IMC Chicago's ABCL Position: Q4 2025 in Review

IMC Chicago sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 92,973 shares — an estimated $415K sold.

IMC Chicago first reported a position in ABCL in Q3 2025 and held it in 1 quarter. The position peaked at $468K in Q3 2025. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • IMC Chicago reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • IMC Chicago sold 92,973 AbCellera Biologics shares in Q4 2025, an estimated $415K.
  • IMC Chicago first reported a position in AbCellera Biologics in Q3 2025 and held it in 1 quarter.
  • IMC Chicago's AbCellera Biologics position peaked at $468K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.